The HPA axis: what we mean when we say "stress response system."

The Hypothalamic-Pituitary-Adrenal (HPA) axis is the body's primary stress-response system. When you encounter a stressor — deadline, traffic, a difficult conversation — your hypothalamus signals your pituitary, which signals your adrenal glands to release cortisol.

Cortisol is good. It mobilizes glucose, sharpens focus, and suppresses non-urgent processes (digestion, immune surveillance) so you can deal with the immediate situation. The system is meant to spike, then return to baseline.

Chronic activation — through caffeine, sleep deprivation, prolonged stress — keeps cortisol elevated when it should fall, and depressed when it should rise. Researchers call this HPA axis dysregulation. It's well-documented in stress physiology literature, particularly in studies of shift workers, parents of newborns, and chronic-stress occupational groups.

• Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53(4):865-871.
• McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87(3):873-904.
• Lovallo WR. Cortisol secretion patterns in addiction and addiction risk. Int J Psychophysiol. 2006;59(3):195-202.

Adaptogens are a category of botanicals studied for their effects on stress-response physiology. Ashwagandha (Withania somnifera) is the most-researched adaptogen in published clinical trials. The Indian Ministry of AYUSH classifies it as a Rasayana — a category of traditional medicine focused on restoration of balance.

The Chandrasekhar 2012 trial.

KSM-66 is a standardized full-spectrum root extract of Withania somnifera, manufactured by Ixoreal Biomed (India). It is the most-studied form of ashwagandha in the published clinical literature, with over 22 human trials to date covering stress, cognitive performance, sleep quality, and exercise recovery.

The most-cited trial is Chandrasekhar et al. 2012, a randomized, double-blind, placebo-controlled study of 64 adults with chronic stress (Perceived Stress Scale ≥ 20). Participants received either 300mg KSM-66 twice daily (600mg total) or matching placebo, for 60 days.

Secondary endpoints showed significant improvements in Perceived Stress Scale and General Health Questionnaire scores. No significant adverse events were reported. The full text is publicly available via PubMed Central.

Subsequent trials have replicated the cortisol-reduction effect at varying doses (240mg/day to 600mg/day) and durations (8 weeks to 12 weeks). The dose-response curve is roughly linear within this range; effects plateau above 600mg/day in most studies.

• Salve J et al. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019;11(12):e6466.
• Lopresti AL, Smith SJ, Drummond PD. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract. Medicine (Baltimore). 2019;98(37):e17186.
• Auddy B et al. A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans. JANA. 2008;11(1):50-56.

On our 250mg dose

HolisticNex Mushroom Gummies use 250mg KSM-66 per 2-gummy serving. This is below the per-dose used in Chandrasekhar's trial (300mg, twice daily). Two reasons:

Format constraint. KSM-66 is a bitter root extract. At higher per-serving doses, gummy palatability degrades sharply. We tested formulations up to 400mg KSM-66 per serving in product development; 250mg was the highest dose that held the "real fruit, no earthy aftertaste" bar without compromising the gummy format.

Daily ingredient framing. A daily supplement isn't designed to replicate clinical trial protocols. The frame is structure-function support — not pharmacological intervention. We don't claim Chandrasekhar's outcomes will replicate proportionally at 250mg. We claim that 250mg KSM-66 is a meaningful dose, used in the published adaptogen research, taken daily.

NGF synthesis and brain biology.

Hericium erinaceus (Lion's Mane) contains two unique compound classes — hericenones (concentrated in the fruiting body) and erinacines (concentrated in the mycelium). Both have been shown in vitro and in animal studies to stimulate Nerve Growth Factor (NGF) synthesis in cell cultures.

NGF is a protein essential for the growth, maintenance, and survival of neurons — specifically cholinergic neurons in the basal forebrain, which play a role in learning and memory.

The translational research is more limited. The most-cited human trial is Mori et al. 2009, a small (n = 30) double-blind placebo-controlled study of older adults with mild cognitive impairment. The Lion's Mane group received 3,000mg/day of fruiting-body powder for 16 weeks; cognitive scores improved on the Revised Hasegawa Dementia Scale during treatment but returned to baseline 4 weeks after discontinuation.

• Lai PL et al. Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus, from Malaysia. Int J Med Mushrooms. 2013;15(6):539-554.
• Mori K et al. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372.
• Saitsu Y et al. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40(4):125-131.

On our 500mg Lion’s Mane dose

HolisticNex uses 500mg of 100% fruiting-body Lion’s Mane within our 2,500mg daily 7-mushroom blend — every dose disclosed on the label. Most clinical trials have used 1,000mg–3,000mg/day of isolated Lion’s Mane — our blend amount is intentionally a daily-support dose, not an acute pharmacological intervention, and every milligram is disclosed on the label.

We use fruiting body specifically (not mycelium-on-grain) because hericenones are concentrated in the fruiting body. The next section explains why this matters.

The Nammex 2016 testing data.

Nammex (Nutraceutical Mushroom Extracts) is a long-established mushroom extract supplier. In 2016, founder Christopher Hobbs published independent lab testing of 19 commercial mushroom supplements available on the US market.

The findings, summarized:

The reason is mechanical. Mycelium is grown on grain (typically rice or oats) in commercial production. The resulting product is harvested with the substrate intact — meaning what's sold as "mushroom mycelium powder" in the US market is often grain with mycelium attached. The Nammex testing found starch content of 50–70% in many mycelium-on-grain products, vs <5% in fruiting body extracts.

Beta-glucans are the primary bioactive compounds in functional mushrooms. Concentrating them — via fruiting body extraction — is the difference between meaningful daily dosing and starch-with-trace-mushroom.

This is why HolisticNex Mushroom Gummies use 100% fruiting body extract for all 7 mushrooms (Lion's Mane, Reishi, Cordyceps, Chaga, Maitake, Turkey Tail, Shiitake). Independent third-party testing of our finished product confirms beta-glucan content consistent with fruiting body benchmarks. Lab reports are available with the 3-bag bundle.

What we don't claim — and why.

A brand could read the studies above and write copy like:

1. We're not 600mg KSM-66 dosed. Our 250mg per serving is below the per-dose used in Chandrasekhar's trial. Outcomes won't replicate proportionally. We've never tested HolisticNex itself in a clinical trial; making product-level cortisol-reduction claims based on Chandrasekhar's KSM-66 data would be a category error.

2. We're not a clinical product. We're a daily supplement. The regulatory frame for a supplement under DSHEA is "helps support" structure-function language — not "treats," "cures," or "reverses." Crossing that line isn't just policy non-compliance — it's a misrepresentation of what daily ingredients actually do.

3. Individual results vary. The Chandrasekhar trial measured a population mean of subjects with Perceived Stress Scale ≥ 20. Your daily routine, sleep quality, diet, exercise, and stress all change what happens for you. No supplement — ours or anyone's — can promise specific outcomes for an individual.

This is the math. Nothing more.

References, in full.

For the readers who want primary sources. Most of these are open-access; PubMed Central IDs are listed where applicable.

• Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255-262. PMC3573577
• Salve J, Pate S, Debnath K, Langade D. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019;11(12):e6466.
• Lopresti AL, Smith SJ, Drummond PD. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186.
• Lopresti AL, Smith SJ. Ashwagandha (Withania somnifera) for the treatment and enhancement of mental and physical conditions: a systematic review of human trials. J Herbal Med. 2021;28:100434.
• Auddy B, Hazra J, Mitra A, Abedon B, Ghosal S. A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: a double-blind, randomized, placebo-controlled study. JANA. 2008;11(1):50-56.
• Lai PL, Naidu M, Sabaratnam V, et al. Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus, from Malaysia. Int J Med Mushrooms. 2013;15(6):539-554.
• Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372.
• Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40(4):125-131.
• Hobbs C. Mushroom Powders: A Comparison of Beta-Glucan Content. Nammex industry whitepaper, 2016.
• Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53(4):865-871.
• McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87(3):873-904.
• Lovallo WR. Cortisol secretion patterns in addiction and addiction risk. Int J Psychophysiol. 2006;59(3):195-202.